Fasting reverses drug-resistance in hepatocellular carcinoma through p53-dependent metabolic synergism
J. Krstic, I. Reinisch, K. Schindlmaier, M. Galhuber, N. Berger, N. Kupper, E. Moyschewitz, M. Auer, H. Michenthaler, C. Noessing, M. R. Depaoli, J. Ramadani-Muja, S. Stryeck, M. Pichler, B. Rinner, , A. Prokesch
This study shows that fasting enhances the effectiveness of sorafenib in hepatocellular carcinoma by reversing drug resistance through p53-dependent metabolic changes.
bioRxiv · Feb 10, 2021Cancer Biology